CONGRESS OF THE EUROPEAN COLLEGE OF VETERINARY INTERNAL MEDICINE - COMPANION ANIMALS

PLATINUM SPONSORS

Posted: 08-05-2017

ROYAL CANIN

"5-year commitment to the ECVIM-CA congress"

Royal Canin is known as an innovator in the world of cat and dog nutrition. Developing precise nutritional solutions for the dietary management of many conditions, some examples include: 
• Anallergenic – incorporating an extreme feather hydrolysate as its primary protein source. It offers clinicians and their patients extreme refinement in a sustainable product and is of increasing interest in the management of patients with chronic diarrhea
• Fiber Response – to help manage chronic constipation in cats
• Gastro-Intestinal Low Fat in the case of canine pancreatitis
Royal Canin is a long-term partner of EVCIM-CA and is committed to promoting internal medicine amongst young vet. Every year, the company offers free registrations to ECVIM Congress and the lucky winners (allocated per country and on a first-come-first-served basis) are also invited to a pre-congress, Thursday night dinner where they can meet experienced specialists and share their passion for internal medicine.


www.royal-canin.com

Please also visit the new Veterinary Focus website:
http://vetfocus.royalcanin.com

 

 

BOEHRINGER INGELHEIM

Boehringer Ingelheim Animal Health
On January 1st, 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, please visit https://www.boehringer-ingelheim.com/animal-health/animal-health 

Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales. For more information, please visit www.boehringer-ingelheim.com

 


« Previous page